BioMarin Pharm Dividend yield

BioMarin Pharm is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. BioMarin Pharm is a company from USA, and his stocks are publicly traded.

BioMarin Pharm paid a total dividend of 0 million USD last year, for a market value of 14,144 millions (Market Cap 14,065 millions). Dividend per share of BioMarin Pharm is 0.00 USD, and his stock market price 77.29 USD.

According to the chart below where dividend yield is displayed, BioMarin Pharm, has a dividend yield of 0%, amount in contrast with the positive dividend offered by both the market average and companies from USA, Health Care industry, and Pharmaceuticals and Biotechnology sector. This lack of dividends of BioMarin Pharm might harm the evolution of share price if the company is not clearly expanding his business.

In addition, you should compare BioMarin Pharm dividend yield with other Pharmaceuticals and Biotechnology companies or firms from USA.

BioMarin Pharm Dividend Payout

About the ability of BioMarin Pharm to maintain his current dividend of USD 0.00 per share, an amount that accounts for 0.00%, we should study its payout ratio both on earnings and on cash-flows (see chart below). BioMarin Pharm payout on ernings is currently 0.00%, which is lower than the market average and companies in his industry and sector.

The following figure shows payout ratios over earnings and cashflow of BioMarin Pharm, compared againt world market average, USA companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.

BioMarin Pharm Dividend History

Year	Yield	USD	Paypout	Shares*
Present	0.00%	0.00	0.00%	183
2020	0.00%	0.00	0.00%	181
2019	0.00%	0.00	0.00%	179
2018	0.00%	0.00	0.00%	177
2017	0.00%	0.00	0.00%	175
2016	0.00%	0.00	0.00%	171
2015	0.00%	0.00	0.00%	160

*In millions

BioMarin Pharm Stock performance

Finally, last moth BioMarin Pharm showed a return of -8.20% compared to a worldwide -1.33% average, and a -3.33% of Health Care firms. Over the last year, the company obtained a 1.60% versus a worldwide performance of a 31.58%. More detailed information can be seen in the following graph for USA and Pharmaceuticals and Biotechnology firms.